← Leaderboards
Jason Zell
University Of California-Irvine
$1,301,538
Attributed
$1,694,149
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $295.2K · FY2009–25$500K$375K$250K$125K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,694,149 · 4
By mechanism
K23$711,491 · 1
R61$588,916 · 1
R50$392,534 · 1
M01$1,208 · 1
Top collaborators
- Eric W Chak2 shared
- Moon S Chen2 shared
Most similar at University Of California-Irvine
Same institution · by research overlap
- Joel E Milam$8,376,620
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsMalignant NeoplasmsColon CarcinomaColonAffectSitePrincipal InvestigatorArginineCollectionTissuesBiopsyPolyaminesOralRecurrenceEndoscopyHigh RiskDiagnosisAspirinColorectal CancerCancer PatientDietary RestrictionBiomarkerIntakeUrine
Grant awards (9)
Advancing novel cancer preventive and therapeutic strategies across the modern NCI clinical trial networks$196,267
R50 · FY2025 · CA · contact PI
Advancing novel cancer preventive and therapeutic strategies across the modern NCI clinical trial networks$196,267
R50 · FY2024 · CA · contact PI
Enhancing Electronic Health Systems to Decrease the Burden of Colon Cancer, Lung Cancer, Obesity, Vaccine-Preventable Illness, and Liver Cancer (CLOVER)$293,756
R61 · FY2021 · AG
Enhancing Electronic Health Systems to Decrease the Burden of Colon Cancer, Lung Cancer, Obesity, Vaccine-Preventable Illness, and Liver Cancer (CLOVER)$295,160
R61 · FY2020 · AG
Risk reduction through polyamine inhibition among colorectal carcinoma patients$179,143
K23 · FY2012 · CA · contact PI
Risk reduction through polyamine inhibition among colorectal carcinoma patients$178,465
K23 · FY2011 · CA · contact PI
Risk reduction through polyamine inhibition among colorectal carcinoma patients$178,369
K23 · FY2010 · CA · contact PI
PHASE IIA CLINICAL BIOMARKER TRIAL OF ASPIRIN AND ARGININE RESTRICTION IN COLON$1,208
M01 · FY2010 · RR · contact PI
Risk reduction through polyamine inhibition among colorectal carcinoma patients$175,514
K23 · FY2009 · CA · contact PI